Altimmune, Inc. (ALT) Stock Price & Analysis
Altimmune, Inc. (ALT) closed at USD 2.36 on Thursday, October 15, 2026, up 2.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.31; the Oct 15, 2026 session ranged USD 2.29–2.38 on volume of 3,343,495 shares. Market capitalization is $459.06M, with a 52-week range of USD 2.29–6.44 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALT.md
Key facts (ALT)
- 1 of 80 tracked superinvestors hold ALT (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 17.11 (range 11–28).
- Total return with dividends: 1Y -39.3% vs S&P 500 +18.1%; 5Y -80.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.14, revenue estimate $0K.
Superinvestors (SEC 13F-HR, Q2 2026) (ALT)
1 of 80 tracked investors hold ALT. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.06% | $20.4M | New position |
Analysts (ALT)
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 17.11 (low 11, high 28).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Evercore ISI Group | Target lowered | Outperform | $18 → $17 |
| 2026-06-22 | Leerink Partners | Initiated | Outperform | $10 |
Total return (dividends reinvested) (ALT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -39.3% | -80.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -39.4% | -27.7% |
| Volatility (annualized) | 70.5% | 97.8% |
| Max drawdown | -62.6% (Jan 2026→Oct 2026) | -90.3% (Aug 2022→Oct 2023) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 2.36 |
|---|---|
| Change | ▲ 2.16% (up) |
| Previous Close | USD 2.31 |
| Open | USD 2.31 |
| Day Range | USD 2.29 – 2.38 |
| 52-Week Range | USD 2.29 – 6.44 |
| Volume | 3,343,495 shares |
| Market Cap | $459.06M |
| Exchange | NGM |
Technical Analysis (ALT)
Nexqual's technical model rates ALT "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.29 (oversold) |
| vs SMA50 | Below (USD 3.01) |
| MACD | -0.2 (negative) |
Analyst Ratings (ALT)
Wall Street analysts rate ALT "Buy" based on 10 analysts, with a mean price target of USD 17.11 (range USD 11–28), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 17.11 |
| High Target | USD 28 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (ALT)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.12 vs est -0.13 ▲ beat |
| 2026-03-31 | USD -0.18 vs est -0.25 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.24 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.27 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (ALT)
| Total Revenue | $31,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -318493.55% |
| Profit Margin | +0.00% |
| ROE | -28.88% |
| Debt / Equity | 0.08 |
| Current Ratio | 26.78 |
| Total Cash | $326.28M |
| Total Debt | $36.02M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$67.55M (-164746.3% of revenue) |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (ALT)
Nexqual rates Altimmune, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +105% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $326M cash vs $36M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$68M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -29%, ROA -17.2% |
Ownership (ALT)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +77.98% |
| Shares Outstanding | 194.52M |
| Float | 164.34M |
| Short % of Float | +23.72% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (ALT)
Altimmune, Inc. is led by Jerome Benedict Durso (age 57), Chairman, CEO & President, per Nexqual as of October 16, 2026 at 05:19 UTC.
| Chairman, CEO & President | Jerome Benedict Durso (age 57) |
|---|---|
| Chief Scientific Officer | M. Scot Roberts (age 66) |
| Chief Financial Officer | Gregory L. Weaver (age 69) |
| Chief Technology Officer | Bertrand Georges |
| Vice President of Investor Relations | Luis Sanay C.F.A. |
Major Backers & Investors (ALT)
Notable institutional backers of Altimmune, Inc. include Deep Track Capital, Lp, TCG Crossover Management, LLC, Marshall Wace LLP, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 9.9% |
| TCG Crossover Management, LLC | 5.14% |
| Marshall Wace LLP | 3.52% |
| Viking Global | 3.44% |
| RA Capital Management, L.P. | 3.34% |
| Fidelity | 1.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 14.74% |
| Vanguard Group | 14% |
| State Street | 8.51% |
| Geode Capital | 2.58% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt